viewSUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals shares rise on securing anagrelide cancer patent in Japan

SUDA is the only company in the world with patents covering the use of anagrelide in treatment or prevention of metastatic disease in the bone or lung.

SUDA Pharmaceuticals Ltd - SUDA Pharmaceuticals shares rise on securing anagrelide cancer patent in Japan
The company’s shares are trading about 10% higher intra-day, at 4.3 cents

SUDA Pharmaceuticals Ltd (ASX:SUD) confirmed that the Japanese Patent Office has accepted its patent application for anagrelide to treat cancer and the patent will proceed to grant.

The patent titled “Use of Anagrelide for Treating Cancer” has an expiry date of December 2035.

“Significant market opportunity”

Chief executive officer Dr Michael Baker said: “To have the Japanese Patent Office grant this patent is a great step in the right direction for the anagrelide program.

“With a population of almost 130 million people, a granted patent in Japan represents a significant market opportunity.

“In conjunction with our granted European patent, this further strengthens our ability to capture maximum value from the anagrelide program”.

Rationale for Anagrelide use in cancer

Anagrelide is an FDA and EMA approved drug used to reduce elevated platelets and lower the thrombotic risk in myeloproliferative diseases associated with high platelet counts.

Recent research has demonstrated the proactive role that platelets play in facilitating the growth and spread of cancer, in addition to suppressing immune responses to cancer.

It has also been shown that cancer cells can trigger a negative feedback loop, sending out chemicals to signal to the body to produce more platelets.

Solid tumour types where increased platelet levels have been reported to occur in a significant proportion of the patient population include melanoma, mesothelioma, ovarian, vulvar, cervical, renal cell, lung, glioblastoma, pancreatic, endometrial and colorectal cancer.

Working with Dr Richard Franklin, who was involved in the early develop and registration of anagrelide in Europe and is now the project director for the anagrelide program, SUDA continues to make progress developing a pharmaceutical grade oral spray formulation for anagrelide.

Quick facts: SUDA Pharmaceuticals Ltd

Price: 0.034 AUD

Market: ASX
Market Cap: $5.71 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SUDA Pharmaceuticals Ltd named herein, including the promotion by the Company of SUDA Pharmaceuticals Ltd in any Content on the Site, the...



Musgrave Minerals Ltd's Rob Waugh delighted after hitting 85 metres at 11.6...

Musgrave Minerals Ltd's (ASX:MGV) (FRA:6MU) Rob Waugh says drilling at the new Starlight discovery is going 'very well' following news they've hit 85 metres at 11.6 g/t. ''It's close to surface, the mineralisation is starting at about six vertical metres down''. ''It's exciting, we're...

23 hours, 42 minutes ago

2 min read